Comprehensive Stock Analysis of Oxbridge Re Holdings Limited(NASDAQ:OXBR): Interpace Diagnostics Group, Inc.(NASDAQ:IDXG)

0
4

Many analysts are providing their Estimated Earnings analysis for Oxbridge Re Holdings Limited and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.

Some buy side analysts are also providing their Analysis on Oxbridge Re Holdings Limited, where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 0.4 and Average Volume (3 months) is 10.85 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -5.5%. The Return on Equity (ROE) value stands at -6.6%. While it’s Return on Investment (ROI) value is -3.8%.

While looking at the Stock’s Performance, Oxbridge Re Holdings Limited currently shows a Weekly Performance of 2.21%, where Monthly Performance is 12.18%, Quarterly performance is -37.42%, 6 Months performance is 4.53% and yearly performance percentage is -17.13%. Year to Date performance value (YTD perf) value is 23.48%. The Stock currently has a Weekly Volatility of 4.88% and Monthly Volatility of 7.16%.

Interpace Diagnostics Group, Inc. (IDXG) will report its next earnings on Apr 22 AMC. The company reported the earnings of $-2.95/Share in the last quarter where the estimated EPS by analysts was $-0.74/share. The difference between the expected and actual EPS was $-2.21/share, which represents an Earnings surprise of -298.6%.

Many analysts are providing their Estimated Earnings analysis for Interpace Diagnostics Group, Inc. and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $-1.22/share. These analysts have also projected a Low Estimate of $-1.55/share and a High Estimate of $-1.01/share.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for Interpace Diagnostics Group, Inc. as 8.93 Million. According to these analysts, the Low Revenue Estimate for Interpace Diagnostics Group, Inc. is 8.8 Million and the High Revenue Estimate is 9.2 Million. The company had Year Ago Sales of 6.33 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for IDXG to be -16%. They are projecting Next Quarter growth of -30%. For the next 5 years, Interpace Diagnostics Group, Inc. is expecting Growth of 65.47% per annum, whereas in the past 5 years the growth was 25.09% per annum.

Some buy side analysts are also providing their Analysis on Interpace Diagnostics Group, Inc., where 5 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 0.44 and Average Volume (3 months) is 79.25 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -43.7%. The Return on Equity (ROE) value stands at -105.2%. While it’s Return on Investment (ROI) value is -166.8%.

While looking at the Stock’s Performance, Interpace Diagnostics Group, Inc. currently shows a Weekly Performance of 4.67%, where Monthly Performance is 3%, Quarterly performance is -47.4%, 6 Months performance is -16.92% and yearly performance percentage is -31.27%. Year to Date performance value (YTD perf) value is 3%. The Stock currently has a Weekly Volatility of 9.21% and Monthly Volatility of 9.40%.

SHARE